An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

NCT05469919 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Malignancies

Interventions

DRUG: Ceralasertib

Sponsor

AstraZeneca